A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

January 27, 2025

Study Completion Date

March 27, 2025

Conditions
Autosomal Dominant Polycystic Kidney DiseaseADPKDPolycystic Kidney, Autosomal Dominant
Interventions
DRUG

RGLS8429

Solution for subcutaneous injection

DRUG

Placebo

Solution for subcutaneous injection

Trial Locations (21)

18017

Northeast Clinical Research Center, Bethlehem

21201

University of Maryland School of Medicine, Nephrology, Baltimore

30904

Southeastern Clinical Research Institute, LLC, Augusta

32224

Mayo Clinic - Florida, Jacksonville

32806

Elixia, Orlando

48066

St. Clair Nephrology Research, Roseville

52242

University of Iowa, Iowa City

55905

Mayo Clinic - Rochester, Rochester

60617

University of Chicago, Chicago

60643

Research by Design, LLC, Chicago

66160

University of Kansas Medical Center Jared Grantham Kidney Institute, Kansas City

67214

Witchita Nephrology Group, PA, Wichita

75390

University of Texas Southwestern Medical Center, Dallas

83202

CARE Institute, Chubbuck

83404

The Idaho Kidney Institute, Idaho Falls

83706

CARE Institute, Boise

85206

Centricity Research Phoenix Multispecialty, Mesa

90022

Academic Medical Research Institute, Los Angeles

98104

Swedish Center for Comprehensive Care, Seattle

06510

Yale Nephrology Outpatient Clinic, New Haven

02111

Tufts Medical Center, Boston

All Listed Sponsors
lead

Regulus Therapeutics Inc.

INDUSTRY